Brought to you by 
Ablynx signs on AbbVie to develop and commercialize ALX0061
03 Aug 2020
Executive Summary
Antibody therapeutics developer Ablynx NV enlisted the help of Abbott’s early-2013 spin-off AbbVie Inc. to develop and commercialize its ALX0061, a Nanobody aimed at inflammatory diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ablynx signs on AbbVie to develop and commercialize ALX0061
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice